Synovion Laboratories Private Limited

Synovion Laboratories Private Limited - pharma in Delhi, India. FY 2026 financials & compliance.
CIN U74999DL2013PTC252897 Incorporated 27 May 2013 ROC Delhi HQ Delhi, India
Active Private Limited Company pharma
Data last updated
Revenue · FY 2024
₹3.01 Cr
▲ 10% YoY
Net profit · FY 2024
₹12.67 Lakh
Net margin 4.2%
EBITDA · FY 2024
₹19.25 Lakh
EBITDA margin 6.4%
Authorised capital
₹1 Lakh
Registered with MCA
Paid-up capital
₹1 Lakh
Issued & subscribed
Open charges
₹50 Lakh
Secured borrowings
Company age
13 yrs
Est. 2013
Directors on board
2
As per MCA filings

About Synovion Laboratories Private Limited

Data last updated:

Synovion Laboratories Private Limited is a private limited company based in Delhi, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 27 May 2013 and has been in existence for over 13 years.

The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U74999DL2013PTC252897. Its GSTIN is 07AATCS1103J1ZA (Delhi).

The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Gaurav Palia and Jharna Roy.

Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Unit No – 202 Plot No – 3A 2nd Floor, Krishna Plaza Sector – 8 Rohini, Delhi, India – 110085.

As per the financials filed for FY 2024, the company reported a revenue of ₹3.01 Cr, a growth of 10% compared to the previous year. For the same year it recorded a net profit of ₹12.67 Lakh (net margin 4.2%) and EBITDA of ₹19.25 Lakh (EBITDA margin 6.4%). Revenue has grown at a compounded annual rate (CAGR) of 26% over three years and 22% over five years.

The company is associated with 1 brand: Synovion Laboratories. As per MCA filings, the company has open charges of ₹50 Lakh on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website synovion.in.

Company details

CIN U74999DL2013PTC252897
Registration Number 252897
Incorporation Date 27 May 2013
ROC Delhi
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2024
Date of Balance Sheet 31 March 2024
Compliance Status Active Compliant

Contact details

Synovion Laboratories Private Limited's registered office is in Delhi, Delhi. Its website is synovion.in. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Registered Address
    Unit No – 202 Plot No – 3A 2nd Floor, Krishna Plaza Sector – 8 Rohini, Delhi, India – 110085
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Synovion Laboratories Private Limited, buy the company report.

Comprehensive company report
Synovion Laboratories Private Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Synovion Laboratories operates one associated brand: Synovion Laboratories. Each brand links to its own profile.

BrandDescriptionWebsite
Manufacturer of generic tablets, capsules, syrup, and injectablessynovion.in

Business activity

The main business activity of Synovion Laboratories is trade. In detail, this covers wholesale trading.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
GTradeG1Wholesale Trading

To see the full business activity and turnover split of Synovion Laboratories Private Limited, buy the company report.

Financials of Synovion Laboratories Private Limited

FY 2024 filings available

Synovion Laboratories Private Limited reported revenue of ₹3.01 Cr (up 10% YoY) for FY 2024.

Revenue · FY 2024
₹3.01 Cr ▲ 10%
Net profit · FY 2024
₹12.67 Lakh margin 4.2%
EBITDA · FY 2024
₹19.25 Lakh margin 6.4%

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
1 year
▲ 10%
3 years · compounded
▲ 26%
5 years · compounded
▲ 22%
EBITDA CAGR growth
1 year
▲ 21%
3 years · compounded
▲ 35%
5 years · compounded
▲ 40%

Revenue has grown at a compounded annual rate (CAGR) of 22% over five years, including 10% growth in the latest year. EBITDA rose 21% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary

MetricsFY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Profit and Loss Statement
Revenue from Operations
Other Income
Total Revenue
Cost of Materials Consumed
Employee Benefit Expense
Finance Costs
Depreciation and Amortisation
Other Expenses
Total Expenses
EBITDA₹19.25 Lakh
Profit Before Tax
Tax Expense
Net Profit (PAT)₹12.67 Lakh
Balance Sheet
Share Capital
Reserves and Surplus
Net Worth (Total Equity)
Long-term Borrowings
Short-term Borrowings
Trade Payables
Total Liabilities
Fixed Assets
Investments
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

MetricsFY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Profitability
EBITDA Margin6.4%
Net Profit Margin4.2%
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Assets (ROA)
Liquidity and Debt
Current Ratio
Quick Ratio
Debt-to-Equity Ratio
Interest Coverage Ratio
Efficiency and Growth
Asset Turnover
Receivable Days
Payable Days
Inventory Days
Revenue Growth
Net Profit Growth

To see the full financial statements and ratios of Synovion Laboratories Private Limited, buy the company report.

Board of directors of Synovion Laboratories Private Limited

Synovion Laboratories has 2 current directors and 2 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Gaurav PaliaDirector27 May 201313 Years 5 MonthsCurrent
Jharna RoyDirector30 Sep 20197 Years 0 MonthsCurrent

Auditor

Synovion Laboratories Private Limited is audited by Rajnish Dudeja & Associates for the financial year 2023.

Auditor firmFinancial yearFirm registration number
Rajnish Dudeja & AssociatesFY 2023094705

Shareholding

The shareholding of Synovion Laboratories Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.

Shareholder categoryFY 2023FY 2022FY 2020FY 2019FY 2018
Promoters
Domestic institutional investors (DII)
Foreign institutional investors (FII)
Public
Others

To see the full shareholding pattern of Synovion Laboratories Private Limited, buy the company report.

Charges & borrowings

Open charges
₹50 Lakh
Satisfied charges
None
Breakdown by lending institutions
Others₹0.50 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
13 Mar 2025101076104Others₹50 LakhOpen

Total charge records: 1 View all charges

MSME payment delays

No delayed payments to MSME suppliers are on our record for Synovion Laboratories Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

GST

Synovion Laboratories has 1 GST registration: 1 active.

Total GSTINs
1
Active
1
GSTINStateStatusRegistered on
07AATCS1103J1ZADelhiActive01 Jul 2017

To see the full GST registrations and return filing status of Synovion Laboratories Private Limited, buy the company report.

Recent activity

Synovion Laboratories Private Limited has 4 board changes on record since 2013: 2 appointments and 2 cessations. The latest: Jharna Roy ceased to be Additional Director on 28 Oct 2020.

Charges
A charge with Others amounted to Rs. 50.00 Lakh with Charge ID 101076104 was registered on 13 Mar 2025.
AGM
Synovion Laboratories Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.
Filing
Synovion Laboratories Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Delhi.
Ceased
Jharna Roy ceased to be Additional Director.
Ceased
Gourav Gupta ceased to be Director.
Appointed
Jharna Roy was appointed as Director.
Appointed
Gaurav Palia was appointed as Director.
Incorporation
27 May 2013
Synovion Laboratories Private Limited was registered on 27 May 2013 with Roc Delhi & aged 13 years 5 months as per MCA records.

Frequently asked questions

Synovion Laboratories is an active private limited company based in Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 27 May 2013 (13+ years old) and is registered under CIN U74999DL2013PTC252897.

Synovion Laboratories has 2 current directors:

The latest financial statements of Synovion Laboratories on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.

The GSTIN of Synovion Laboratories is 07AATCS1103J1ZA, registered in Delhi.

The CIN (Corporate Identification Number) of Synovion Laboratories is U74999DL2013PTC252897. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Synovion Laboratories was incorporated on 27 May 2013, making it 13+ years old. It is registered with the Registrar of Companies, Delhi.

Jharna Roy ceased to be Additional Director on 28 Oct 2020. Gourav Gupta ceased to be Director on 01 Oct 2019. Jharna Roy was appointed as Director on 30 Sep 2019. Synovion Laboratories has 4 board changes on record in total.

Synovion Laboratories can be reached through the website synovion.in. Its registered office is in Delhi, India.

The registered office of Synovion Laboratories is at Unit No – 202 Plot No – 3A 2nd Floor, Krishna Plaza Sector – 8 Rohini, Delhi, India – 110085.

Synovion Laboratories operates in the pharma industry, in the drug formulation and development segment.